Vestal Point Capital LP Grows Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Vestal Point Capital LP raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 108.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 520,000 shares of the biotechnology company's stock after acquiring an additional 270,000 shares during the period. Ascendis Pharma A/S makes up approximately 4.2% of Vestal Point Capital LP's investment portfolio, making the stock its 4th largest position. Vestal Point Capital LP owned about 0.86% of Ascendis Pharma A/S worth $71,588,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Ascendis Pharma A/S during the 4th quarter worth $28,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Quarry LP bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth $96,000. Finally, Tower Research Capital LLC TRC raised its stake in Ascendis Pharma A/S by 195.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 664 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $1.95 during trading on Thursday, hitting $160.05. 345,783 shares of the company traded hands, compared to its average volume of 487,500. The firm has a market capitalization of $9.76 billion, a price-to-earnings ratio of -22.54 and a beta of 0.41. The business's fifty day moving average is $157.63 and its 200 day moving average is $143.12. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wedbush upped their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $180.00 to $250.00 in a research note on Monday, May 5th. Cantor Fitzgerald restated an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a report on Monday, May 12th. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, Royal Bank of Canada increased their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.